| Drug pricing: Bitter pill Jul 31 / FT.com | Will AbbVie (ABBV) Surprise This Earnings Season? - Analyst Blog Jul 24 / Zacks.com |
| 3 Eye-Catching Health Care Stocks this Earnings Season - Earnings ESP Jul 31 / Zacks.com | Glaxo (GSK) Slips on Disappointing Q2 Earnings, Cuts View - Analyst Blog Jul 24 / Zacks.com |
| Tax Inversion: Boon for Firms & Investors, Bane for U.S. Treasury - Analyst Blog Jul 31 / Zacks.com | Gilead Stock's Great Expectations and Giant Opportunity Jul 23 / MotleyFool.com |
| Wall Street wants tax holiday to be a QE4 Jul 31 / CNNMoney.com | Biotech Stock Roundup: AbbVie's Tax Inversion, Amgen Drug Scores in Phase 3 - Analyst... Jul 23 / Zacks.com |
| Tax Inversion Puts These 3 Mutual Funds in Focus - Best of Funds Jul 30 / Zacks.com | Healthcare Spending Uptrend: 3 Medical Stocks for Strong Growth - Analyst Blog Jul 23 / Zacks.com |
| Pfizer refuses to rule out tax inversion deals Jul 30 / FT.com | Johnson & Johnson Announces $5B Share Buyback - Analyst Blog Jul 22 / Zacks.com |
| Windstream soars on Reit spin-off plan Jul 29 / FT.com | Allergan, a Valeant Takeover Target, Plans 1,500 Job Cuts - Analyst Blog Jul 22 / Zacks.com |
| Pfizer Beats on Q2 Earnings, Revs Despite Generic Pressures - Analyst Blog Jul 29 / Zacks.com | 3 Things You Need to Watch on Gilead Sciences Inc. Earnings Call Jul 22 / MotleyFool.com |
| Novo Nordisk Diabetes Drug Xultophy Gets Positive CHMP View - Analyst Blog Jul 29 / Zacks.com | 3 Quotes From Johnson & Johnson's Conference Call You Need to Read Jul 22 / MotleyFool.com |
| Novartis Division Gets European Approval for Simbrinza - Analyst Blog Jul 28 / Zacks.com | Shire's Q2 Earnings Strong but Overshadowed by AbbVie Deal - Analyst Blog Jul 22 / Zacks.com |
| Markets Little Changed Ahead Of The Federal Reserve's Policy Decision Jul 28 / Benzinga | Here's What You Need to Know About AbbVie and GlaxoSmithKline's Upcoming Earnings Jul 22 / MotleyFool.com |
| Consumer and pharma groups swap assets Jul 28 / FT.com | AbbVie Set to Acquire UK-Based Shire in Q4 - Analyst Blog Jul 21 / Zacks.com |
| Hospira Eyeing Bid For Danone Unit in Latest Tax Deal Jul 28 / TheStreet.com | Pfizer's Stock Falls Ill as the Dow Tumbles Jul 21 / MotleyFool.com |
| Will This Analyst Upgrade Help AbbVie (ABBV) Stock Today? Jul 28 / TheStreet.com | Welcome to Ireland, AbbVie Jul 21 / MotleyFool.com |
| 5 Toxic Stocks You Should Sell This Summer Jul 25 / TheStreet.com | Allergan Beats on Q2 Earnings, Ups View & Plans 13% Job Cut - Analyst Blog Jul 21 / Zacks.com |
| Humira Still Key to AbbVie Jul 25 / MotleyFool.com | Monday Links: Excessive Valuations Jul 21 / StockTwits |
| Roche's 1H14 Earnings & Revenues Up Y/Y, Outlook Reaffirmed - Analyst Blog Jul 25 / Zacks.com | With Shire, Did AbbVie Count Its Chickens Before They Hatched? Jul 18 / MotleyFool.com |
| AbbVie Q2 Earnings Top on Humira Sales, Shire In Focus - Analyst Blog Jul 25 / Zacks.com | AbbVie Inc. Wins the Shire Jul 18 / MotleyFool.com |
| How Will AbbVie (ABBV) Stock React To Its Second Quarter Earnings Beat? Jul 25 / TheStreet.com | Shire chief's $10m 'golden hello' at AbbVie Jul 18 / FT.com |
| Today's Top Health Care Headlines: AbbVie and GlaxoSmithKline Jul 25 / MotleyFool.com | What You Need to Know About Johnson & Johnson's Best-Selling Drugs Jul 18 / MotleyFool.com |
| Stocks: 6 things to know before the open Jul 25 / CNNMoney.com | Shire demands assurances in backroom fight over tax inversion Jul 18 / FT.com |
| Shire, ArmaGen Ink Licensing Agreeement for AGT-182 - Analyst Blog Jul 24 / Zacks.com | What crisis? U.S. stocks soar Jul 18 / CNNMoney.com |
| Obama call for US corporate tax crackdown Jul 24 / FT.com | Today's Top Health Care Stocks to Watch: AbbVie, Gentiva Health Services and Shire Jul 18 / MotleyFool.com |
| Pharma, Biotech M&As Heat Up: Tax Inversion in Focus - Zacks Analyst Interviews Jul 24 / Zacks.com | Drugmaker in $54.7 billion merger aimed at cutting U.S. taxes Jul 18 / CNNMoney.com |
| Pharma, Biotech M&As Heat Up: Tax Inversion in Focus - Industry Outlook Jul 24 / Zacks.com | AbbVie seals B#32bn takeover of Shire Jul 18 / FT.com |
+0.16 / +0.31%
.
